CLASS ACT? ion? Neither! This malingering suit is, very clearly, DEAD IN THE WATER.
Bavi IS TRANSFORMATIONAL! More than doubled survival in the phase2 trial...............................And in SUNRISE Bavi performed as was expected. And, certainly, those expectations were high, and aimed at becoming the new Standard of Care, SOC, replacing Docetaxel. (Not against Docetaxel plus a third line Opdivo follow-up treatment.)
That SUNRISE data will be of interest to potential partners...It will carry weight for any future acquirer, and will be in Peregrine’s back pocket for show and tell.
But, I think we see pure I-O combinations for Bavi from here on going forward in collaborations and the eventual acquisition.
Thank you Habitual.
IMO
sunstar